EAM Investors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

EAM Investors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-884,969	Closed	-$5.93M	–	372
2022 Q3	$5.93M	Buy	884,969 +34,322	+4%	+$208K	1.29%	1
2022 Q2	$3.58M	Buy	+850,647	New	+$3.37M	0.87%	8
2018 Q1	–	Sell	-34,905	Closed	-$903K	–	384
2017 Q4	$903K	Buy	+34,905	New	+$703K	0.16%	217
2016 Q2	–	Sell	-120,423	Closed	-$1.65M	–	391
2016 Q1	$1.65M	Sell	120,423 -12,894	-10%	-$186K	0.26%	178
2015 Q4	$2.53M	Sell	133,317 -804	-0.6%	-$17.5K	0.33%	145
2015 Q3	$2.52M	Buy	134,121 +51,802	+63%	+$880K	0.4%	100
2015 Q2	$1.23M	Sell	82,319 -115	-0.1%	-$1.75K	0.14%	269
2015 Q1	$1.25M	Buy	+82,434	New	+$1.15M	0.14%	273
2014 Q4	–	Sell	-303,142	Closed	-$3.82M	–	379
2014 Q3	$3.82M	Buy	+303,142	New	+$2.94M	0.78%	5

Other funds holding CNCE

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Investors's CNCE Position: Q4 2022 in Review

EAM Investors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 884,969 shares — an estimated $5.93M sold.

EAM Investors first reported a position in CNCE in Q3 2014 and held it in 9 quarters. The position peaked at $5.93M in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

EAM Investors reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
EAM Investors sold 884,969 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $5.93M.
EAM Investors first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 9 quarters.
EAM Investors's Concert Pharmaceuticals, Inc. position peaked at $5.93M in Q3 2022.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.